268 related articles for article (PubMed ID: 32459892)
21. Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
Yang J; Hu M; Bai X; Ding X; Xie L; Ma J; Fan B; Yu J
Medicine (Baltimore); 2019 Sep; 98(39):e17231. PubMed ID: 31574833
[TBL] [Abstract][Full Text] [Related]
23. Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients.
Chivu-Economescu M; Herlea V; Dima S; Sorop A; Pechianu C; Procop A; Kitahara S; Necula L; Matei L; Dragu D; Neagu AI; Bleotu C; Diaconu CC; Popescu I; Duda DG
Gastric Cancer; 2023 Nov; 26(6):934-946. PubMed ID: 37668884
[TBL] [Abstract][Full Text] [Related]
24. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
25. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
26. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance.
Lu F; Dong Y; Li Q; Wang M
Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
[TBL] [Abstract][Full Text] [Related]
27. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract][Full Text] [Related]
28. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
Shen H; Ji Y; Zhou D; Zhang Y; Wang W; Sun J; Zhang W
Hematology; 2019 Dec; 24(1):392-398. PubMed ID: 30890046
[TBL] [Abstract][Full Text] [Related]
29. Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
Qu Y; Wang H; Liu H; Sun X; Li J; Yu H
Biomed Res Int; 2021; 2021():8811751. PubMed ID: 33987445
[TBL] [Abstract][Full Text] [Related]
30. Maternal soluble PD-1 levels are significantly increased in women with preeclampsia.
Gu Y; Morgan J; Lewis DF; Cooper DB; McCathran CE; Wang Y
Am J Reprod Immunol; 2020 Jan; 83(1):e13193. PubMed ID: 31585483
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
[TBL] [Abstract][Full Text] [Related]
32. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
33. Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors.
Kushlinskii NE; Alferov AA; Timofeev YS; Gershtein ES; Bulycheva IV; Bondarev AV; Shchupak MY; Sokolov NY; Polikarpova SB; Efimova MM; Dzampaev AA; Sushentsov EA; Aliev MD; Musaev ER
Bull Exp Biol Med; 2020 Nov; 170(1):64-68. PubMed ID: 33231796
[TBL] [Abstract][Full Text] [Related]
34. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
[TBL] [Abstract][Full Text] [Related]
35. Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit.
Zhao Y; Jia Y; Li C; Shao R; Fang Y
Shock; 2019 Mar; 51(3):289-297. PubMed ID: 29702526
[TBL] [Abstract][Full Text] [Related]
36. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
Okuyama M; Mezawa H; Kawai T; Urashima M
Front Immunol; 2019; 10():86. PubMed ID: 30833943
[No Abstract] [Full Text] [Related]
37. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
[No Abstract] [Full Text] [Related]
38. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract][Full Text] [Related]
40. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
